|
See related Leustatin inj information |
|
|
|
Manufacturer |
Cilag |
|
Distributor |
Hong Kong: DKSH/Macau: Four Star |
|
Contents |
Cladribine |
|
Indications |
Active hairy cell leukaemia, nonresponsive B-cell chronic lymphocytic leukaemia. |
|
Dosage |
Hairy cell leukaemia Single course of 0.09 mg/kg/day by continuous IV infusion for 7 consecutive days. Chronic lymphocytic leukaemia See lit. |
|
Special Precautions |
Monitor for signs of haematologic & non-haematologic toxicity. Delay or discontinue drug if neurotoxicity or renal toxicity occurs. |
|
Adverse Drug Reactions |
Myelosuppression (including neutropenia, anaemia & thrombocytopenia), fever, fatigue, nausea, rash, headache.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
ATC Classification |
L01BB04 - cladribine ; Belongs to the class of antimetabolites, purine analogues. Used in the treatment of cancer. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Leustatin injection |
|
Leustatin (single-use) 1 mg/1 mL x 10 mL x 1's |
|
|
|
Manufacturer: |
Cilag |
|
Distributor: |
Hong Kong: DKSH
Macau: Four Star
|
|
|
|
